Enhanced Stability and Efficiency in Radiopharmaceutical Compositions

The present invention relates to improvements in the stability, efficiency, and preparation of radiopharmaceutical compositions comprising tetrofosmin or its pharmaceutically acceptable salts, addressing the limitations of existing compositions.

The original patent disclosed a stable radiopharmaceutical composition of tetrofosmin or its pharmaceutically acceptable salts. However, the composition's stability and efficiency can be further improved. The new inventive concept solves the problem of limited shelf-life, inefficient preparation, and reduced radiochemical purity by introducing modified storage conditions, automated mixing devices, and pH-adjusting agents.

The new inventive concept comprises a system for preparing a radiopharmaceutical composition, wherein the kit is stored in a container with a modified atmosphere to improve stability. Additionally, the invention includes a method for enhancing the shelf-life of a lyophilized kit, comprising storing the kit in a container with a reduced oxygen content. Furthermore, the invention introduces a radiopharmaceutical composition comprising tetrofosmin or its pharmaceutically acceptable salts, and a biocompatible reductant, wherein the reductant is selected to improve the stability of the composition. The system for reconstituting a radiopharmaceutical composition includes an automated mixing device to improve efficiency. The method for preparing a radiopharmaceutical composition comprises adding a pH-adjusting agent to improve the radiochemical purity of the composition.

The new claims introduce novel modifications to the original patent's composition and preparation method, including the use of modified storage conditions, automated mixing devices, and pH-adjusting agents. These innovations provide an inventive step over the original patent, as they address specific limitations and improve the overall performance of the radiopharmaceutical composition.

Alternative embodiments of the inventive concept may include the use of different biocompatible reductants, pH-adjusting agents, or automated mixing devices. Variations of the invention may also include the application of the modified storage conditions and automated mixing devices to other radiopharmaceutical compositions.

The inventive concept has significant commercial potential in the field of radiopharmaceuticals, particularly in diagnostic imaging and nuclear medicine. The improved stability, efficiency, and preparation of radiopharmaceutical compositions can lead to increased adoption and revenue growth in the target industries.